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Background. The goals of this study were to determine the effective bolus dose of alfentanil
required for successful tracheal intubation during inhalation induction using sevoflurane 5%
without neuromuscular block in children, and whether nitrous oxide reduces these doses.
Methods. Fifty paediatric patients, aged 3–10 yr, were randomly assigned to one of the two
groups. Subjects received either sevoflurane 5% in oxygen 100% (O2 group, n¼25) or sevoflur-
ane 5% in oxygen 40% and nitrous oxide 60% (N2O group, n¼25) through a face mask. One
minute after inhalation induction, a predetermined dose of alfentanil was injected over 15 s.
The alfentanil dose was determined using Dixon’s up-and-down method, starting from alfenta-
nil 14 mg kg21. The trachea was intubated 3 min after inducing anaesthesia.
Results. The ED50 [95% confidence interval (CI)] of alfentanil for successful tracheal intuba-
tion was 11.5 (9.9–13.1) and 8.6 (7.4–9.8) mg kg21 in the O2 and N2O groups, respectively.
The ED50 of the N2O group was significantly lower than that of the O2 group (P¼0.0146).
From isotonic regression, 50% effective dose (ED50) (95% CI) of alfentanil in the O2 and N2O
groups was 11.4 (9.9–13.0) and 6.5 (5.0–8.1) mg kg21, respectively.
Conclusions. The effective bolus dose of alfentanil for successful tracheal intubation was 11.5
mg kg21 in 50% of children during inhalation induction using sevoflurane 5% without neuro-
muscular blocking agent. Addition of nitrous oxide 60% in oxygen reduced the effective alfen-
tanil dose by 25%.
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Sevoflurane is frequently used for inhalation induction of
anaesthesia and tracheal intubation in children without the
use of neuromuscular blocking drugs.1 During sevoflurane
inhalation induction, the addition of an opioid has been
shown to allow rapid tracheal intubation2 3 and decrease the
target cerebral concentration of sevoflurane needed to
perform tracheal intubation in children,4 and therefore
reduces some side-effects associated with the use of
high-concentration sevoflurane. Nitrous oxide also decreases
the minimum alveolar concentration of halogenated
anaesthetics, and Swan and colleagues5 reported that nitrous
oxide and sevoflurane suppress the responses to tracheal
intubation in a linear and additive manner in children.
To date, there are no reports of the bolus dose of alfen-
tanil for successful tracheal intubation during sevoflurane
inhalation induction in paediatric patients. The purpose of
this study was to determine the bolus dose of alfentanil to
provide successful tracheal intubation during inhalation
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induction using sevoflurane 5% and oxygen 100% with or
without nitrous oxide in the absence of neuromuscular
blocking agent in children.
Methods
This study was approved by the institutional review board,
and written informed consent for the study was obtained
from the parents. Fifty children, ASA I or II, aged 3–10 yr,
undergoing general anaesthesia for short elective surgery
lasting ,1 h were enrolled. Children with a history of
reactive airway disease and a suspected difficult airway
were excluded.
To prevent the possible delay in time to intubation, a 24 G
cannula was inserted in the dorsum of the hand and a dex-
trose 5% in NaCl 0.2% solution was infused before arriving
in the operating theatre. Once in the operating theatre, all
subjects were monitored with ECG, pulse oximeter, and a
non-invasive arterial pressure device. The end-tidal concen-
tration of CO2 and sevoflurane was measured continuously
at the elbow of the breathing circuit using a precalibrated gas
monitor (at a sampling flow rate of 250 ml min21). The sub-
jects were randomized using a computer-generated sequence
of random numbers and allocated to one of the two groups
using a sequential sealed envelope technique. Subjects
received either oxygen 100% (O2 group, n¼25) or oxygen
40% and nitrous oxide 60% (N2O group, n¼25) during
induction. Glycopyrrolate 0.004 mg kg21 was administered
before inducing anaesthesia. According to their group, a
semi-closed anaesthetic circuit was primed with sevoflurane
5% in oxygen 100%, or sevoflurane 5% in oxygen 40% and
nitrous oxide 60% for 2 min. Inhalation induction was
initiated via a face mask with a fresh gas flow rate of 5 litre
min21. Initially, the subjects breathed spontaneously, and
ventilation was assisted manually to maintain an end-tidal
CO2 of 4.25–4.79 kPa when they became apnoeic. One
minute after beginning inhalation induction, a predetermined
dose of alfentanil was injected over 15 s. Three minutes after
the beginning of inhalation induction, the trachea was intu-
bated with a cuffed tracheal tube.
The bolus dose of alfentanil for each subject was deter-
mined by the response of the previously tested subject using
the up-and-down sequential allocation method of Dixon and
Massey6 (2 mg kg21 as a step size). The first subject was
tested at alfentanil 14 mg kg21 in each group. If intubation
failed, the alfentanil dose was increased by 2 mg kg21. If it
was successful, it was then decreased by 2 mg kg21. The
anaesthesiologist who performed and assessed the intubating
conditions was unaware of the alfentanil dose and the use of
N2O. Blinding to the treatment group was assured by an
opaque partition placed between anaesthetic machine and
the observer. Intubation conditions were evaluated according
to a scoring system described by Viby-Mogensen and
colleagues7 (Table 1). Successful intubation was defined
as excellent or good intubating conditions. Rocuronium
0.3 mg kg21 was administered in the case of unacceptable
intubating conditions due to strong movement, inadequate
jaw relaxation, closed vocal cords, or sustained coughing.
Any evidence of chest wall rigidity, such as difficulty in ven-
tilation, wheezing, changing compliance, or change in the
slope of the end-tidal CO2 waveform, was noted. Clinically
significant hypotension or bradycardia, defined as .30%
decrease in mean arterial pressure (MAP) or heart rate (HR)
compared with baseline at anaesthetic induction, respect-
ively, was treated with atropine or ephedrine as appropriate.
MAP, HR, SpO2, end-tidal CO2, and sevoflurane concen-
trations were recorded at anaesthetic induction, and before
and 1 min after intubation.
Statistical analyses
Statistical analyses were performed using SAS 9.1 for
Windows (SAS Institute Inc., Cary, NC, USA). Data are
expressed as mean (SD) or number of subjects. The 50%
effective dose (ED50) of alfentanil was defined as the alfen-
tanil dose at which there was a 50% probability of successful
tracheal intubation. The up-and-down sequences were ana-
lysed using the formula reported by Dixon and Massey,6
which enabled the ED50 to be calculated with a 95% confi-
dence interval (CI). Data were also subjected to isotonic
regression estimators for calculating the ED50 and ED95 and
the 95% CI in each group. An adjusted response probability
was easily calculated by the pooled-adjacent-violators algor-
ithm (PAVA) and the CI was estimated by a bootstrapping
approach.8 The subject characteristics and induction profiles
were compared using Student’s t-test. Changes in haemo-
dynamic data were compared by repeated-measures ANOVA.
A P-value of ,0.05 was considered significant. The sample
size was calculated based on the assumed standard deviation
of the alfentanil dose from a previous study.9 Twenty-four
patients were required in each group to detect a mean differ-
ence of alfentanil 2 mg kg21 between the groups at a power
of 0.9 and a P-value of 0.05. The sample size was increased
to 50 patients to allow for dropouts.
Results
A total of 48 subjects completed the study; one from each
group showed severe excitation during induction and were
excluded from the statistical analyses (Fig. 1).
Table 1 Assessment of intubating conditions. Intubating conditions:
Excellent, all criteria are excellent; Good, all criteria are either excellent or
good; Poor, the presence of a single criterion listed under ‘poor’
Variables Intubating conditions
Acceptable Unacceptable
Excellent Good Poor
Ease of laryngoscopy
( jaw relaxation)
Easy Fair Difficult
Vocal cord position Abducted Intermediate Closed
Vocal cord movement None Moving Closing
Airway reaction (coughing) None Diaphragm Sustained (.10 s)
Movement of the limbs None Slight Vigorous
Alfentanil with sevoflurane for intubation
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There were no significant differences in the subject
characteristics between the two groups (Table 2).
However, the end-tidal sevoflurane concentration was sig-
nificantly higher in the N2O group than that in the O2
group before and after tracheal intubation (Table 2).
Intubating conditions were good or excellent (successful
intubation) in 12 of 24 and 14 of 24 patients in the O2 and
N2O groups, respectively. Intubating conditions were poor
(failed intubation) in 12 of 24 and 10 of 24 patients in the
O2 and N2O groups, respectively. The most common event
leading to failed intubation was sustained coughing, which
occurred in six of 12 and eight of 10 patients in the O2
and N2O groups, respectively. Vigorous movements and
poor jaw relaxation were observed in seven of 12 and two
of 10 patients in the O2 and N2O groups, respectively.
Closed vocal cords or closing vocal cord movement was
observed in two of 12 and four of 10 subjects in the O2
and N2O groups, respectively.
Table 3 lists the MAP and HR during induction of
anaesthesia. The MAP before intubation decreased signifi-
cantly compared with baseline, and returned to baseline
after tracheal intubation in both groups. Compared with
baseline, HR increased significantly after intubation in
both groups. There were no significant differences in MAP
or HR between the two groups.
Figure 2 shows the sequences of the alfentanil doses for
successful and unsuccessful tracheal intubation in the two
groups. Using the formula of Dixon and Massey,6 the
ED50 of alfentanil in the O2 and N2O groups (95% CI)
was 11.5 (9.9–13.1) and 8.6 (7.4–9.8) mg kg21,
Table 2 Patients characteristics and induction profiles. Values are mean
(range) or mean (SD). Pre E0CO2, end-tidal CO2 concentration just before
intubation; Post E0CO2, end-tidal CO2 concentration 1 min after intubation; Pre E
0
Sevo, end-tidal sevoflurane concentration just before intubation; Post E0 Sevo,
end-tidal sevoflurane concentration 1 min after intubation. *P,0.05 compared
with the O2 group
O2 (n524) N2O (n524)
Sex (M/F) 10/14 13/11
Age (yr) 7.6 (4.4–10.0) 7.7 (4.0–10.0)
Weight (kg) 26.3 (5.2) 25.1 (5.8)
Pre E0CO2 (mm Hg) 31.2 (3.2) 32.7 (2.3)
Post E0CO2 (mm Hg) 35.8 (3.1) 36.2 (2.5)
Pre E0 Sevo (%) 3.3 (0.1) 3.4 (0.2)*
Post E0 Sevo (%) 3.4 (0.1) 3.7 (0.2)*
Table 3 Haemodynamic data during anaesthesia induction. Values are mean
(SD). MAP, mean arterial pressure; HR, heart rate. *P,0.05 compared with
the baseline value within the group. No significant differences between the
groups were noted
Group Baseline Before
intubation
1 min after
intubation
MAP (mm Hg) O2 80.0 (7.7) 65.6 (13.5)* 79.6 (14.4)
N2O 78.6 (8.0) 64.0 (13.9)* 82.5 (19.5)
HR (beats min21) O2 90.2 (10.7) 92.8 (17.8) 115.6 (16.7)*
N2O 90.7 (13.1) 94.1 (15.6) 119.5 (19.3)*
SpO2 (%) O2 99.8 (0.5) 100 (0.0) 99.8 (0.6)
N2O 99.9 (0.3) 100 (0.0) 98.5 (2.8)
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Fig 2 Sequences of the dose of alfentanil for successful intubation in the
O2 group (A) and the N2O group (B) using the technique of up-and-down
sequential allocation. The horizontal lines represent the mean and 95%
CI. The ED50 of alfentanil in the O2 and N2O groups (95% CI) was 11.5
(9.9–13.1) and 8.6 (7.4–9.8) mg kg21, respectively.
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Fig 1 The CONSORT flowchart.
Kwak et al.
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respectively. The ED50 of the N2O group was significantly
lower than that of the O2 group (P¼0.0146). Figure 3
shows the PAVA response rate in the two groups. Using
isotonic regression estimated from the PAVA response rate,
the ED50 (95% CI) of alfentanil in the O2 and N2O groups
was 11.4 (9.9–13.0) and 6.5 (5.0–8.1) mg kg21, respect-
ively. Estimates of the ED95 of alfentanil in the O2 and
N2O groups (95% CI) were 14.0 (12.1–15.9) and 10.7
(9.5–11.9) mg kg21, respectively.
There were no adverse respiratory events such as laryn-
gospasm, and SpO2 remained above 90% in all children
throughout the study period. No child suffered clinically
significant bradycardia or hypotension.
Discussion
This study of 48 paediatric subjects undergoing general
anaesthesia has, first, determined the ED50 of alfentanil for
successful tracheal intubation during inhalation induction
without neuromuscular block and, secondly, provided
clinical evidence that N2O (60%) reduces the ED50 of
alfentanil by 25%. It is of note that the 95% CI of the
alfentanil ED50 and ED95 values for the O2 and N2O
groups did not overlap.
Inhalation induction with sevoflurane has been shown to
be suitable for tracheal intubation without a neuromuscular
blocking agent in children.10 11 Adding a potent and
short-acting opioid (alfentanil or remifentanil) during
sevoflurane inhalation induction was reported to improve
conditions for tracheal intubation without neuromuscular
blocking agents in children.3 12 A previous study reported
that the dose of remifentanil for successful tracheal intuba-
tion was 0.56 mg kg21 in 50% of children during inhala-
tion induction using sevoflurane 5% in oxygen.2 The ED50
of alfentanil (11.5 mg kg21) in this study is consistent
with that of remifentanil, considering that remifentanil
is 20 times as potent as alfentanil.13 In addition, using
the STANPUMP software based on a paediatric pharmaco-
kinetic model of alfentanil,14 the predicted effect-site
concentrations of alfentanil at the ED50 were 49 and
37 ng ml21 in the O2 and N2O groups, respectively.
In a busy clinical setting, a rapid induction technique
has practical advantages. Among other opioids, alfentanil
has a peak onset of 1 min, which does not delay induction
time. The duration of alfentanil is 20–30 min and there-
fore can be ideal for short surgeries that last about 30 min.
Although remifentanil also has short onset and even
shorter duration of action, alfentanil was used in this study
because it can be used as a bolus dose instead of infusion
and is less expensive. In order to fit the conditions similar
to clinical practice, tracheal intubation was attempted
3 min after the start of induction with a mean end-tidal
sevoflurane concentration of 3.3–3.4%. These anaesthetic
induction times and end-tidal sevoflurane concentrations
were comparable with those in the previous study by
Inomata and colleagues.15 They reported that the time to
the end-tidal sevoflurane concentration of 3.0% was 149 s
and the sevoflurane ED50 for tracheal intubation was 3.1%
in children using a rapid method with an inspired sevoflur-
ane concentration of 5% in oxygen.
The end-tidal sevoflurane concentration in this study
was significantly higher in the N2O group before and after
tracheal intubation. Although the difference was only
about 0.1%, which was clinically insignificant, the lower
alfentanil dose required for tracheal intubation in the N2O
group may be explained by the higher sevoflurane concen-
tration before intubation. The pharmacokinetic simulations
of sevoflurane administration using Gas Manw software
(MedMan Simulations, Inc., Chestnut Hill, MA, USA)
also confirmed that the effect-site concentration of sevo-
flurane at the time of intubation was significantly higher in
the N2O group than that in the O2 group (1.3% vs 1.2%,
respectively). Although the difference seems small and
clinically insignificant, the use of anaesthesia depth moni-
tors such as bispectral index or cerebral state index may
have elucidated its effect on the study result.
There are several limitations in this study. Up-and-down
methods are a simple sequential design used to determine
the dose at the 50th quantile. This method reduces the
total number of subjects needed to determine the ED50.
Since anaesthesiologists are interested in the ED95, the
ED95 is often calculated using the isotonic regression esti-
mator with the CIs derived by bootstrapping. Although
isotonic regression has favourable backup analysis for
obtaining the ED50 with a smaller bias and tighter CIs
compared with standard probit or logit regression, which
is likely to produce biased estimators,8 the extrapolation of
the ED95 from small up-and-down data can be imprecise.
Another limitation is the definition of successful intuba-
tion, which was defined as excellent or good according to
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Fig 3 PAVA response rate in the O2 and N2O groups. The 50% effective
dose (ED50) (95% CI) of alfentanil in the O2 and N2O groups was 11.4
(9.9–13.0) and 6.5 (5.0–8.1) mg kg21, respectively. The ED95 (95% CI)
of alfentanil estimated from the PAVA response rate in the O2 and N2O
groups was 14.0 (12.1–15.9) and 10.7 (9.5–11.9) mg kg21, respectively.
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a scoring system described by Viby-Mogensen and
colleagues.7 However, Mencke and colleagues16 reported
that only excellent conditions should be considered as
successful intubation because the quality of tracheal
intubation contributes to laryngeal morbidity and excellent
conditions are less frequently associated with postoperative
hoarseness and vocal cord sequelae. If this were to be con-
sidered, the ED50 of alfentanil would have been higher.
In conclusion, the bolus dose (ED50) of alfentanil for
successful tracheal intubation was 11.5 mg kg21 during
sevoflurane 5% induction in oxygen 100% without a neu-
romuscular blocking agent in children. The addition of
nitrous oxide 60% reduced the dose of alfentanil by 25%.
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